CASI Pharmaceuticals, Inc. (CASI) Form 6-K — Jul 15, 2026
CASI Pharmaceuticals announced it received a final award from the Hong Kong International Arbitration Centre in its dispute with Juventas Co., Ltd. The tribunal rejected all allegations that CASI breached agreements regarding the commercialization of CNCT-19. The ruling determined that Juventas wrongfully terminated the agreements in March 2024.
Key figures
- Award Amount
- well over RMB 100 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.